These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18472687)

  • 1. Gadolinium and kidney disease: are your patients at risk?
    Hollister D
    Nephrol Nurs J; 2008; 35(2):196-7. PubMed ID: 18472687
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gadolinium: a true problem for the nephrologists?].
    Balducci A; Tamburrini O
    G Ital Nefrol; 2008; 25(1):3-4. PubMed ID: 18264906
    [No Abstract]   [Full Text] [Related]  

  • 3. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 5. [Nephrogenic systemic fibrosis: another problem for patients with chronic renal failure].
    Michelet PR; Chopard CS; Martin PY; Vallée JP
    Rev Med Suisse; 2008 Mar; 4(147):576-8, 580. PubMed ID: 18402015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?
    Singh M; Davenport A; Clatworthy I; Lewin J; Deroide F; Hubbard V; Rustin MH
    Br J Dermatol; 2008 Jun; 158(6):1358-62. PubMed ID: 18363754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis.
    High WA; Ayers RA; Cowper SE
    J Am Acad Dermatol; 2007 Apr; 56(4):710-2. PubMed ID: 17289213
    [No Abstract]   [Full Text] [Related]  

  • 8. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
    Edward M; Quinn JA; Mukherjee S; Jensen MB; Jardine AG; Mark PB; Burden AD
    J Pathol; 2008 Apr; 214(5):584-93. PubMed ID: 18220317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced computed tomography or magnetic resonance imaging: a choice between contrast medium-induced nephropathy and nephrogenic systemic fibrosis?
    Thomsen HS; Marckmann P; Logager VB
    Acta Radiol; 2007 Jul; 48(6):593-6. PubMed ID: 17611863
    [No Abstract]   [Full Text] [Related]  

  • 10. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrogenic systemic fibrosis: experimental studies confound prevailing theory of free gadolinium as a causative factor.
    Jakobsen J
    Acta Radiol; 2008 Jul; 49(6):616-7. PubMed ID: 18568551
    [No Abstract]   [Full Text] [Related]  

  • 12. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute phase reaction to gadolinium-DTPA in dialysis patients.
    Steen H; Giannitsis E; Sommerer C; Bahner U; Brandl M; Merbach C; Merten C; Ritz E; Katus HA; Zeier M; Schwenger V
    Nephrol Dial Transplant; 2009 Apr; 24(4):1274-7. PubMed ID: 19042926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- and interindividual comparison studies with gadopentetate dimeglumine.
    Shellock FG; Parker JR; Pirovano G; Shen N; Venetianer C; Kirchin MA; Spinazzi A
    J Magn Reson Imaging; 2006 Dec; 24(6):1378-85. PubMed ID: 17078095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal failure and gadolinium. The number of documented cases is rising.
    Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
    [No Abstract]   [Full Text] [Related]  

  • 16. Gadolinium-induced nephrogenic systemic fibrosis in patients with kidney and liver disease.
    Shenoy C
    Am J Med; 2008 Jan; 121(1):e11; author reply e13. PubMed ID: 18187056
    [No Abstract]   [Full Text] [Related]  

  • 17. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gadolinium-DTPA tolerance and clinical safety].
    Niendorf HP; Brasch RC
    Rontgenpraxis; 1997 Dec; 50(12):354-63. PubMed ID: 9492559
    [No Abstract]   [Full Text] [Related]  

  • 19. Nephrogenic systemic fibrosis: considerations for the cardiologist.
    Rofsky NM
    JACC Cardiovasc Imaging; 2008 Jul; 1(4):457-9. PubMed ID: 19356467
    [No Abstract]   [Full Text] [Related]  

  • 20. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.